Why Adaptive Biotechnologies Stock Is Back in Focus

Adaptive Biotechnologies (ADPT) is drawing attention after reporting full year 2025 results, with sales of US$276.98 million, a net loss of US$59.5 million, and fresh 2026 revenue guidance for its MRD business.

The earnings release and 2026 MRD revenue guidance appear to be a key backdrop for recent trading. The share price is US$16.04, with a 3.22% 1-day share price return and a 13.76% 90-day share price return. The 1-year total shareholder return of 92.56% contrasts with a 5-year total shareholder return showing a 74.62% decline, suggesting strong recent momentum following a more challenging longer history.

If you are looking beyond a single biotech name, this could be a good moment to see which other healthcare focused AI companies are on the move using our 25 healthcare AI stocks.

After a sharp 1 year rebound and fresh MRD guidance for 2026, the key question is whether Adaptive Biotechnologies at US$16.04 still offers value or if the market is already pricing in future growth.

Most Popular Narrative: 20.4% Undervalued

At a last close of US$16.04 against a narrative fair value of about US$20.14, the current price sits below what this widely followed view estimates, with that gap hinging on how Adaptive Biotechnologies converts its MRD and immune medicine platforms into future cash flows.

Substantial expansion in the MRD clinical pharma pipeline, evidenced by a growing clinical trial backlog (now at $218 million, up 21% over prior year) and increased use of clonoSEQ as a primary endpoint, forecasts future milestone payments and a high-quality revenue stream as regulatory momentum globally accelerates MRD adoption in drug development.

Want to understand why this narrative still sees upside at today’s price? It hinges on steady revenue compounding, margin lift, and a rich future earnings multiple. Curious how those pieces fit together into that US$20.14 figure? The full narrative lays out the exact growth path and profitability shift behind this valuation call.

Result: Fair Value of $20.14 (UNDERVALUED)

However, there are still watch points, including ongoing company wide losses and heavy dependence on key partners like Genentech and Pfizer to support future progress.

Another Way To Look At Valuation

The narrative fair value points to Adaptive Biotechnologies being undervalued, but the price tag tells a different story. On P/S, the shares trade at 8.9x, well above the US Life Sciences average of 2.8x and a fair ratio of 3.8x. This indicates clear valuation risk if sentiment cools.

Build Your Own Adaptive Biotechnologies Narrative

If you see the numbers differently or simply prefer to rely on your own work, you can build a personalized Adaptive Biotechnologies view in minutes with Do it your way.

A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Ready To Find Your Next Investment Idea?

If Adaptive Biotechnologies has sparked your interest, do not stop here. Use the Simply Wall Street Screener to quickly uncover other opportunities that might suit your portfolio.

• Spot potential long term compounders early by checking out our screener containing 23 high quality undiscovered gems built from companies with strong underlying fundamentals.
• Strengthen the core of your portfolio with our solid balance sheet and fundamentals stocks screener (44 results) that highlights businesses prioritising financial resilience.
• Reduce stress around volatility by scanning our 85 resilient stocks with low risk scores focused on companies with more stable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.